SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Centerra Gold Inc. (“Centerra” or the “Company”) CGAU. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation addresses whether Centerra and certain of its officers and/or directors have engaged […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) IBRX. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation addresses whether ImmunityBio and certain of its officers and/or directors have engaged in […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) JKS. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation concerns whether JinkoSolar and certain of its officers and/or directors have […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) WARM. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation concerns whether ARS and certain of its officers and/or directors have engaged […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Relmada Therapeutics, Inc. (“Relmada” or the “Company”) RLMD. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation addresses whether Relmada and certain of its officers and/or directors have engaged […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors from TriplePoint Venture Growth BDC Corp. (“TriplePoint” or the “Company”) TPVG Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation addresses whether TriplePoint and certain of its officers and/or directors […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of E2open Parent Holdings, Inc. (“E2open” or the “Company”) ETW. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation concerns whether E2open and certain of its officers and/or directors have […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Peloton Interactive, Inc. (“Peloton” or the “Company”) PTON. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation addresses whether Peloton and certain of its officers and/or directors have engaged […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Arrow Financial Corporation (“Arrow” or the “Company”) A ROW. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation addresses whether Arrow and certain of its officers and/or directors have […]
SHAREHOLDER ALERT: Pomerantz law firm investigating claims on behalf of…
NEW YORK, May 28, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) RETA. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980. The investigation concerns whether Reata and certain of its officers and/or directors have engaged […]